NCT lookup

Inclusion Criteria:

* Healthy post-menopausal women.
* Capable of providing informed consent.
* Weight of ≥50 kg and a BMI ≥19 and ≤39 kg/m2.
* Subjects should be able to communicate with clinic staff.

Exclusion Criteria:

* Subjects who have a history of allergy or hypersensitivity to letrozole or any of the inactive ingredients.
* Subjects who have a history of galactose intolerance, severe hereditary lactase deficiency glucose-galactose malabsorption.
* Subjects who have used estrogen or progesterone hormone replacement therapy, thyroid replacement therapy, oral contraceptives, androgens, luteinizing hormone (LH) releasing hormone analogs, prolactin inhibitors, or antiandrogens within prior to Screening.
* Subjects who have used: any medications including St. John's wort or any medications or products known to be potent or moderate inhibitors of CYP P450 3A4.
* Subjects who have been diagnosed with osteoporosis.
* Subjects who have an abnormality at Screening or prior to first dose that in the opinion of the investigator increases the risk of participating in the study.
* Subjects who have any clinically significant abnormal physical examination or laboratory safety findings at screening.
* Subjects who have relevant diseases or clinically significant abnormal relevant findings at Screening, as determined by medical history, physical examination, laboratory, ECG, DEXA, and breast and pelvic examination.
* Subjects who have history of any significant chronic disease.
* History of cancer within the past 5 years with the exception of non-melanoma skin cancer.
* Subjects who have a history of drug-dependence, and recent history of alcoholism or abuse of alcohol.
* Subjects who have received a drug in research or have participated in other clinical trials within 90 days, prior to dosing.
* Any other unspecified reason that, in the opinion of the investigator (or designee) or sponsor, makes the subject unsuitable for enrolment.

• Prague, Czechia